Last updated: February 28, 2026
What is the Drug and Its Current Market Position?
NDC 72578-0133 corresponds to Mepsevii (vestronidase alfa-vjbk), approved by the FDA in August 2017 for the treatment of mucopolysaccharidosis VII (MPS VII, also known as Sly syndrome). It is a recombinant form of human beta-glucuronidase administered via intravenous infusion.
As one of the few approved treatments for MPS VII, Mepsevii has limited competition. Its market penetration remains restricted to rare disease treatment centers and specialized physicians.
Market Size and Patient Population
Incidence and Prevalence
- MPS VII is estimated to affect fewer than 100 patients worldwide.
- U.S. prevalence is approximately 20-40 cases based on orphan disease registries (source: Orphanet [1]).
Market Drivers
- Increased diagnosis rates due to advanced genetic testing.
- Growing awareness and patient registries.
- Expansion of treatment centers.
Sales Data
- U.S. sales in 2022: approximately $30 million (IQVIA, 2023).
- Global sales remain minimal due to the low prevalence.
Market Constraints
- Small patient population.
- High treatment costs.
- Limited approval outside the U.S. and select markets.
Price Analysis
Current Pricing
- List price in the U.S.: roughly $375,000 per year per patient.
- Price per vial: approximately $15,000.
- Dosage: weight-based, typically 4mg/kg every two weeks.
Cost Considerations
- The per-year cost varies by patient weight, with the average patient costing between $350,000 and $400,000 annually.
- Insurance reimbursement policies have aligned with list prices, subject to negotiation.
Price Trends
- No significant recent price adjustments.
- Manufacturers maintain premium pricing due to orphan designation and limited competition.
Competitive Landscape
Approved Alternatives
- No direct competitors for MPS VII.
- Hematopoietic stem cell transplantation exists but with limited efficacy and higher risks.
Emerging Therapies
- No phase 3 or advanced pipeline candidates specifically targeting MPS VII reported.
Future Price and Market Projection
Factors Influencing Price
- Potential introduction of biosimilars is unlikely due to biological complexity and orphan drug protections.
- Pricing may be influenced by negotiations with payers and healthcare systems.
- Manufacturing costs are stable due to established bioprocessing.
Market Growth Projections
| Year |
Estimated Global Sales |
Key Factors |
| 2023 |
$30M |
Steady demand, limited expansions |
| 2024 |
$31M |
Slight growth due to increased diagnosis |
| 2025 |
$32M |
No major price hikes anticipated |
| 2026 |
$33M |
Market saturation, stable prices |
Revenue Outlook
- The small patient base caps growth.
- Price increases are unlikely without new indications or expanded approvals.
Regulatory and Policy Environment
- Orphan drug incentives extend exclusivity until 2027.
- Payer restrictions may limit reimbursement to negotiated rates.
- International markets may adopt different pricing strategies based on local policies.
Key Takeaways
- NDC 72578-0133 (Mepsevii) serves a niche, with limited patient access.
- U.S. list pricing remains around $375,000 annually.
- Sales are projected to grow marginally, constrained by the rare disease status.
- No significant biosimilar competition is expected in the near term.
- Future pricing likely will remain stable unless expanded indications or new competitors emerge.
FAQs
1. What factors could lead to price increases for Mepsevii?
Introduction of new indications, supply chain cost increases, or regional pricing negotiations could elevate prices, but regulatory protections limit rapid hikes.
2. How does the small patient population impact market potential?
It restricts total revenues and growth opportunities, making it less attractive for new entrants or investments beyond niche markets.
3. Are biosimilars a threat in this space?
Unlikely, because manufacturing complex biologics and securing regulatory approval are costly and time-consuming, especially for very rare diseases.
4. How does international pricing compare?
Pricing varies based on healthcare system policies and orphan drug regulations; generally lower outside the U.S. due to price controls.
5. What is the projected impact of new therapies?
Emerging therapies targeting rare lysosomal storage diseases could shift the landscape but are currently at early development stages for MPS VII.
References
- Orphanet. (2023). Mucopolysaccharidosis type VII. https://www.orpha.net/
- IQVIA. (2023). Top Selling Biopharmaceuticals Report.
- U.S. FDA. (2017). Approval of Mepsevii for MPS VII.
